Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a

. 2021 Jan 12 ; 96 (2) : e214-e227. [epub] 20201006

Jazyk angličtina Země Spojené státy americké Médium print-electronic

Typ dokumentu časopisecké články, pozorovací studie, randomizované kontrolované studie, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid33024022

Grantová podpora
UL1 TR003167 NCATS NIH HHS - United States

Odkazy

PubMed 33024022
PubMed Central PMC7905777
DOI 10.1212/wnl.0000000000010991
PII: WNL.0000000000010991
Knihovny.cz E-zdroje

OBJECTIVE: To compare the effectiveness of glatiramer acetate (GA) vs intramuscular interferon beta-1a (IFN-β-1a), we applied a previously published statistical method aimed at identifying patients' profiles associated with efficacy of treatments. METHODS: Data from 2 independent multiple sclerosis datasets, a randomized study (the Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis [CombiRx] trial, evaluating GA vs IFN-β-1a) and an observational cohort extracted from MSBase, were used to build and validate a treatment response score, regressing annualized relapse rates (ARRs) on a set of baseline predictors. RESULTS: The overall ARR ratio of GA to IFN-β-1a in the CombiRx trial was 0.72. The response score (made up of a linear combination of age, sex, relapses in the previous year, disease duration, and Expanded Disability Status Scale score) detected differential response of GA vs IFN-β-1a: in the trial, patients with the largest benefit from GA vs IFN-β-1a (lower score quartile) had an ARR ratio of 0.40 (95% confidence interval [CI] 0.25-0.63), those in the 2 middle quartiles of 0.90 (95% CI 0.61-1.34), and those in the upper quartile of 1.14 (95% CI 0.59-2.18) (heterogeneity p = 0.012); this result was validated on MSBase, with the corresponding ARR ratios of 0.58 (95% CI 0.46-0.72), 0.92 (95% CI 0.77-1.09,) and 1.29 (95% CI 0.97-1.71); heterogeneity p < 0.0001). CONCLUSIONS: We demonstrate the possibility of a criterion, based on patients' characteristics, to choose whether to treat with GA or IFN-β-1a. This result, replicated on an independent real-life cohort, may have implications for clinical decisions in everyday clinical practice.

Zobrazit více v PubMed

Kalincik T, Manouchehrinia A, Sobisek L, et al. . Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain 2017;140:2426–2443. PubMed

Zhao L, Tian L, Cai T, Clagget B, Wei LJ. Effectively selecting a target population for a future comparative study. J Am Stat Assoc 2013;108:527–539. PubMed PMC

Bovis F, Carmisciano L, Signori A, et al. . Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial data. BMC Med 2019;17:113. PubMed PMC

Pellegrini F, Copetti M, Bovis F, et al. . A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis. Mult Scler 2020;26:1064–1073. PubMed

Comi G, Jeffery D, Kappos L, et al. . Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012;366:1000–1009. PubMed

Vollmer TL, Sorensen PS, Selmaj K, et al. . A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol 2014;261:773–783. PubMed

Comi G. CONCERTO: a placebo-controlled trial of oral laquinimod in patients with relapsing-remitting multiple sclerosis. ECTRIMS Online Libr 2017;202596. PubMed

Gold R, Kappos L, Arnold DL, et al. . Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098–1107. PubMed

Fox RJ, Miller DH, Phillips JT, et al. . Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087–1097. PubMed

Lublin FD, Cofield SS, Cutter GR, et al. . Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol 2013;73:327–340. PubMed PMC

Butzkueven H, Chapman J, Cristiano E, et al. . MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler 2006;12:769–774. PubMed

Lyndsey JW, Scott TF, Lynch SG, et al. . The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: design and baseline characteristics. Mult Scler Relat Disord 2013;1:81–86. PubMed

McDonald WI, Compston A, Edan G, et al. . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121–127. PubMed

Polman CH, Reingold SC, Edan G, et al. . Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald criteria.” Ann Neurol 2005;58:840–846. PubMed

Hernan MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol 2016;183:758–764. PubMed PMC

Schumacher GA, Beebe G, Kibler RF, et al. . Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965;122:552–568. PubMed

Mendelez-Torres GJ, Armoiry X, Court R, et al. . Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages. BMC Neurol 2018;18:162. PubMed PMC

Kalincik T, Jokubaitis V, Izquierdo G, et al. . Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. Mult Scler 2015;21:1159–1171. PubMed

Wolinsky JS, Narayana PA, O'Connor Pet al. . Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007;61:14–24. PubMed

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...